Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to keep rare nerve disease in check long-term

NCT ID NCT05405361

Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is a long-term follow-up for people with multifocal motor neuropathy, a rare condition that causes muscle weakness. It tests the safety and effectiveness of a drug called ARGX-117, given intravenously. The trial includes 51 adults who previously took part in an earlier study, and it involves both double-blinded and open-label treatment periods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ARGX-117
What this could lead to
If it works, this could provide a long-term treatment option to control muscle weakness in people with multifocal motor neuropathy.
What could go wrong
This is a small, early-phase extension study with only 51 participants, so results may not apply to everyone. Long-term safety and effectiveness are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

51 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of providing signed informed consent and complying with protocol requirements. Participants must be able to read and write. * Must have completed the double-blinded treatment period of the ARGX-117-2002 trial and considered to be eligible for treatment with ARGX-117. Exclusion Criteria: * Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection. * Clinical evidence of other significant serious diseases, have had a recent major surgery, or who have any other condition, in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk. * Currently participating in another interventional clinical study. * Pregnant or lactating or intend to become pregnant during the trial or within 15 months after last dose of the study drug.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multifocal motor neuropathy (MMN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multifocal motor neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multifocal motor neuropathy (MMN)

Contacts and locations

Locations

  • AZ Sint-Lucas

    Ghent, 9000, Belgium

  • Austin Neuromuscular Center

    Austin, Texas, 78759, United States

  • Azienda Ospedaliera Sant' Andrea

    Rome, 00189, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, 56126, Italy

  • CHU Bordeaux - Groupe Hospitalier Pellegrin

    Bordeaux, 33076, France

  • CHU de Nice

    Nice, 06001, France

  • HonorHealth Neurology

    Scottsdale, Arizona, 85251, United States

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, 46026, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • Hôpital Roger Salengro (CHU de Lille)

    Lille, 59037, France

  • Hôpital de la Pitié Salpétrière

    Paris, 75651, France

  • IRCCS Humanitas Research Hospital

    Rozzano, 20089, Italy

  • IRCCS Ospedale San Raffaele S.r.l.

    Milan, 20132, Italy

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, 1090, Austria

  • Michalski i Partnerzy Lekarze Spolka Partnerska

    Krakow, 31-426, Poland

  • NorthShore University HealthSystem

    Glenview, Illinois, 60026, United States

  • Oxford University Hospitals NHS Trust

    Oxford, OX3 9DU, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, G51 4TF, United Kingdom

  • The Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Universitair Medisch Centrum Utrecht

    Utrecht, 3584 CX, Netherlands

  • Universitatsmedizin Gottingen (UMG) Georg-August-Universitaet

    Göttingen, 37075, Germany

  • University Health Network

    Toronto, Canada

  • University of Minnesota

    Minneapolis, Minnesota, 55414, United States

  • University of Pennsylvania - Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania, 19104, United States

  • Universitätsklinikum Essen

    Essen, 45147, Germany

  • Warszawski Uniwersytet Medyczny

    Warsaw, 02-097, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.